Diagnostic imaging, radiology  

CTI Mirada wins FDA approval to market its Scenium PET scan analysis software

18 January 2005

CTI Molecular Imaging, Inc. (Nasdaq: CTMI), a provider of positron emission tomography (PET) equipment, molecular biomarkers and services, has announced that its subsidiary CTI Mirada Solutions, has been awarded FDA 510(k) clearance to market Scenium, an innovative new quantification tool for the analysis of neurological positron emission tomography (PET) scans.

Scenium display and analysis software has been developed to aid clinicians in accurate assessment and quantification of dementia and other neurological diseases. Initially developed for use in PET studies with fluorodeoxyglucose (FDG), Scenium has the potential to be used with other PET molecular imaging agents in the future.

The software is organized as a series of workflows, each is specific to a particular radiopharmaceutical and disease combination. Based on Mirada's established image fusion techniques, Scenium enables clinicians to compare patients' brain scans to standard normal scans, highlighting differences in uptake. Multiple anatomical regions are highlighted for quick assessment of an image and quantitative comparison with other images and integration into the current reporting workflow of the imaging centre.

The software will be available as a plug-in to a wide variety of viewing workstations, and also for use on a standard PC.

"Developed in direct response to the rapidly expanding market for quantification software, Scenium is expected to achieve a widespread install base during 2005, particularly with the recent approval for reimbursement for some neurological FDG scans," said Christian P Behrenbruch, President of CTI Mirada Solutions.

Mirada plans to release Scenium during spring 2005, following product optimization based on current field trials. The software will be distributed by CTI PETNET, as well as Mirada's OEM/PACS partners.

Additional information is available at: www.mirada-solutions.com/



To top